An in vivo drug repurposing screen and transcriptional analyses reveals the serotonin pathway and GSK3 as major therapeutic targets for NGLY1 deficiency
K. A. Hope, A. R. Berman, R. T. Peterson, C. Y. Chow
This study identifies serotonin pathway modulators and GSK3 inhibitors as potential therapies for NGLY1 deficiency using a Drosophila model and drug screening.
bioRxiv · Nov 10, 2021Pharmacology & Toxicology